Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

Chimeric antigen receptor (CAR) T cells have a tough job. Engineered with a receptor that recognizes molecules decorating the surface of cancer cells, CAR T cells find and kill malignancies. However, ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach ...

Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...

CAR-T Target Luciferase Reporter Cells can be used as a target cancer cell for in vitro killing assay by CD19, CD20, or HER2 CAR-T cells. These luciferase expressing cell lines were derived from ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...